Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide as add-on to SGLT2 inhibitors in type 2 diabetes
NCT02964247Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2017
- Primary completion
- May 2018
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02964247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964247.